Loading...

ObsEva

Nasdaq:OBSV
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OBSV
Nasdaq
$604M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
OBSV Share Price and Events
7 Day Returns
4.3%
NasdaqGS:OBSV
-5.7%
US Biotechs
-3.9%
US Market
1 Year Returns
-0.8%
NasdaqGS:OBSV
-7.9%
US Biotechs
1.4%
US Market
OBSV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ObsEva (OBSV) 4.3% 0.3% 7.4% -0.8% - -
US Biotechs -5.7% -8.7% -6.4% -7.9% 5.5% 10.5%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • OBSV outperformed the Biotechs industry which returned -7.9% over the past year.
  • OBSV underperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
OBSV
Industry
5yr Volatility vs Market

OBSV Value

 Is ObsEva undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ObsEva. This is due to cash flow or dividend data being unavailable. The share price is $13.29.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ObsEva's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ObsEva's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:OBSV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.97
NasdaqGS:OBSV Share Price ** NasdaqGS (2019-05-15) in USD $13.29
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.35x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ObsEva.

NasdaqGS:OBSV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OBSV Share Price ÷ EPS (both in USD)

= 13.29 ÷ -1.97

-6.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ObsEva is loss making, we can't compare its value to the US Biotechs industry average.
  • ObsEva is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ObsEva's expected growth come at a high price?
Raw Data
NasdaqGS:OBSV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
1.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.15x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ObsEva, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ObsEva's assets?
Raw Data
NasdaqGS:OBSV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.87
NasdaqGS:OBSV Share Price * NasdaqGS (2019-05-15) in USD $13.29
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.11x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGS:OBSV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OBSV Share Price ÷ Book Value per Share (both in USD)

= 13.29 ÷ 2.87

4.64x

* Primary Listing of ObsEva.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ObsEva is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess ObsEva's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ObsEva has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OBSV Future Performance

 How is ObsEva expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ObsEva expected to grow at an attractive rate?
  • Unable to compare ObsEva's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare ObsEva's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • ObsEva's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:OBSV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:OBSV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 1.7%
NasdaqGS:OBSV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 87.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:OBSV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:OBSV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 242 14 -59 5
2022-12-31 99 -100 -132 5
2021-12-31 18 -167 -175 7
2020-12-31 0 -134 -139 8
2019-12-31 0 -102 -110 7
NasdaqGS:OBSV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 0 -83
2018-12-31 0 -64 -77
2018-09-30 0 -60 -74
2018-06-30 0 -59 -72
2018-03-31 0 -60 -71
2017-12-31 0 -56 -67
2017-09-30 0 -54 -61
2017-06-30 0 -47 -52
2017-03-31 0 -34 -41
2016-12-31 0 -29 -30
2016-09-30 0 -19 -26
2016-06-30 0 -17 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ObsEva is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • ObsEva's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:OBSV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from ObsEva Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:OBSV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.66 0.60 -1.88 4.00
2022-12-31 -2.38 -1.14 -3.49 4.00
2021-12-31 -2.91 -1.64 -4.08 6.00
2020-12-31 -2.61 -2.20 -3.19 7.00
2019-12-31 -2.35 -1.91 -2.65 7.00
NasdaqGS:OBSV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.97
2018-12-31 -1.91
2018-09-30 -1.93
2018-06-30 -2.09
2018-03-31 -2.21
2017-12-31 -2.25
2017-09-30 -2.30
2017-06-30 -2.11
2017-03-31 -1.79
2016-12-31 -1.40
2016-09-30 -1.29
2016-06-30 -1.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ObsEva will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess ObsEva's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ObsEva has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OBSV Past Performance

  How has ObsEva performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ObsEva's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ObsEva does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ObsEva's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ObsEva's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ObsEva's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ObsEva Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:OBSV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.02 -82.59 15.90 66.67
2018-12-31 0.02 -76.72 14.30 62.87
2018-09-30 0.02 -73.65 13.25 60.87
2018-06-30 0.02 -72.06 13.12 58.88
2018-03-31 0.02 -71.19 13.47 58.20
2017-12-31 0.02 -66.93 12.57 54.91
2017-09-30 0.00 -61.00 12.73 49.15
2017-06-30 0.00 -51.95 11.68 41.22
2017-03-31 0.03 -41.06 8.54 32.95
2016-12-31 0.02 -30.20 6.45 23.71
2016-09-30 0.05 -25.61 4.69 20.49
2016-06-30 0.05 -21.23 3.25 17.80
2016-03-31 0.02 -19.67 3.07 16.38
2015-12-31 0.02 -19.87 2.95 16.89
2014-12-31 0.05 -12.81 1.56 11.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ObsEva has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ObsEva has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ObsEva improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ObsEva's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ObsEva has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OBSV Health

 How is ObsEva's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ObsEva's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ObsEva is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ObsEva's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ObsEva's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 48.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ObsEva Company Filings, last reported 1 month ago.

NasdaqGS:OBSV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 124.66 2.55 117.32
2018-12-31 146.92 0.00 138.64
2018-09-30 164.83 0.00 156.44
2018-06-30 176.65 0.00 166.84
2018-03-31 105.26 0.00 95.44
2017-12-31 122.65 0.00 110.84
2017-09-30 81.57 0.00 68.36
2017-06-30 96.32 0.00 82.08
2017-03-31 111.48 0.00 104.16
2016-12-31 36.04 0.00 25.51
2016-09-30 48.12 0.00 38.91
2016-06-30 55.34 0.00 45.17
2016-03-31 64.68 0.00 54.28
2015-12-31 64.68 0.00 54.28
2014-12-31 5.99 0.00 4.01
  • ObsEva's level of debt (2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if ObsEva's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ObsEva has sufficient cash runway for 1.8 years based on current free cash flow.
  • ObsEva has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 36.1% each year.
X
Financial health checks
We assess ObsEva's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ObsEva has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OBSV Dividends

 What is ObsEva's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ObsEva dividends. Estimated to be 0% next year.
If you bought $2,000 of ObsEva shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ObsEva's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ObsEva's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:OBSV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:OBSV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ObsEva has not reported any payouts.
  • Unable to verify if ObsEva's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ObsEva's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ObsEva has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ObsEva's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess ObsEva's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ObsEva afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ObsEva has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OBSV Management

 What is the CEO of ObsEva's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ernest Loumaye
AGE 66
TENURE AS CEO 6.5 years
CEO Bio

Dr. Ernest Loumaye, MD, PhD, OB/GYN Co-Founded ObsEva SA in November 2012 and has been its Chief Executive Officer since November 2012. Dr. Loumaye co-founded PregLem SA in 2006 and served as its Chief Executive Officer from 2006 to October 19, 2015. Dr. Loumaye has 9 years of experience as Head of Clinical Development for Reproductive Health (RH) at Serono in Geneva and Boston. He serves as Visiting Professor of Reproductive Endocrinology at Louvain University, Brussels. Dr. Loumaye served as Vice President of Medical Sciences, Endocrinology, Research & Development at Ipsen since 2003. Dr. Loumaye served as the Chairman of GenKyoTex S.A until December 21, 2016. He served as Chairman of PregLem SA. Dr. Loumaye serves as Member of PregLem’s Scientific Advisory Board. He serves as Director of ObsEva SA. He served as a Board Member of PregLem SA since 2006. He was a research fellow at the National Institute of Child Health and Human Development, in the US and is the author of over 90 publications in peer-reviewed journals. Dr. Loumaye holds a MD, PhD and OB/GYN degree from Louvain University, Belgium.

CEO Compensation
  • Insufficient data for Ernest to compare compensation growth.
  • Insufficient data for Ernest to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ObsEva management team in years:

3.7
Average Tenure
53
Average Age
  • The tenure for the ObsEva management team is about average.
Management Team

Ernest Loumaye

TITLE
Co-Founder
AGE
66
TENURE
6.5 yrs

Tim Adams

TITLE
Chief Financial Officer
AGE
58
TENURE
2.3 yrs

Jean-Pierre Gotteland

TITLE
Chief Scientific Officer and Head of R&D
AGE
53
TENURE
3.7 yrs

Mario Corso

TITLE
Senior Director of Investor Relations

Elke Bestel

TITLE
Chief Medical Officer & Head of Pharmacovigilance
AGE
52
TENURE
3.7 yrs

Delphine Renaud

TITLE
Personal Assistant to the CSO and Head of R&D

Wim Souverijns

TITLE
Chief Commercial Officer
AGE
47
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the ObsEva board of directors in years:

5.3
Average Tenure
56
Average Age
  • The tenure for the ObsEva board of directors is about average.
Board of Directors

Frank A. G. Verwiel

TITLE
Chairperson of the Board
AGE
56
TENURE
2.4 yrs

Ernest Loumaye

TITLE
Co-Founder
AGE
66

Rafaèle Tordjman

TITLE
Vice-Chairperson
AGE
49

Annette Clancy

TITLE
Director
AGE
64
TENURE
5.5 yrs

Barbara Duncan

TITLE
Director
AGE
53
TENURE
2.4 yrs

Jim Healy

TITLE
Director
AGE
53
TENURE
5.8 yrs

Jacky Vonderscher

TITLE
Independent Director
AGE
63
TENURE
5.6 yrs

Phillip Bennett

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs

Ben Mol

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs

Vassilis Tsatsaris

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess ObsEva's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ObsEva has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OBSV News

Simply Wall St News

Do Institutions Own ObsEva SA (NASDAQ:OBSV) Shares?

But other times, private equity is selling out, having taking the company public. … Private Company Ownership Our data indicates that Private Companies hold 4.3%, of the company's shares. … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Simply Wall St -

Before You Buy ObsEva SA (NASDAQ:OBSV), Consider Its Volatility

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

How Much Of ObsEva SA (NASDAQ:OBSV) Do Insiders Own?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … ObsEva is a smaller company with a market capitalization of US$619m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

How Financially Strong Is ObsEva SA (NASDAQ:OBSV)?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does OBSV's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt

Simply Wall St -

Are You Backing The Right Horse With ObsEva SA (NASDAQ:OBSV)?

operates in the healthcare industry,. … This is illustrated by the growing pressure for innovative, cost-effective treatments, along with higher requirements for transparency from regulators and healthcare providers … Healthcare analysts are forecasting for the entire industry,

Simply Wall St -

How Financially Strong Is ObsEva SA (NASDAQ:OBSV)?

The direct benefit for ObsEva SA (NASDAQ:OBSV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is OBSV will have to adhere to stricter debt covenants and have less financial flexibility. … Does OBSV's growth rate justify its decision for financial flexibility over lower cost of capital

Simply Wall St -

OBSV Company Info

Description

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Details
Name: ObsEva SA
OBSV
Exchange: NasdaqGS
Founded: 2012
$604,392,532
45,477,241
Website: http://www.obseva.com
Address: ObsEva SA
Chemin des Aulx, 12,
Plan-les-Ouates,
Geneva, 1228,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OBSV Common Shares Nasdaq Global Select US USD 26. Jan 2017
DB 22D Common Shares Deutsche Boerse AG DE EUR 26. Jan 2017
SWX OBSN Common Shares SIX Swiss Exchange CH CHF 26. Jan 2017
BMV OBSV N Common Shares Bolsa Mexicana de Valores MX MXN 26. Jan 2017
BATS-CHIXE OBSNZ Common Shares BATS 'Chi-X Europe' GB CHF 26. Jan 2017
Number of employees
Current staff
Staff numbers
43
ObsEva employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 02:49
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/05/12
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.